Archive for the ‘Crispr’ Category

The Regeneron Science Talent Search (STS) alumni community is an illustrious group who hold many honors. This years finalists had the opportunity to hear from one of the many accomplished Society alumni, Feng Zhang (ISEF 1998-1999, STS 2000), at a virtual version of an annual STS traditionthe Alumni Dinner. Each year a distinguished alumnus is invited to speak to the current class. Feng was in the same position as the students when he competed and heard from STS alumni who came before him. Returning to pay it forward and inspire this cohort with his insights as a successful molecular biologist focused on developing tools to improve human health, Feng spoke to the Regeneron STS 2020 finalists about his work with CRISPR-Cas9 systems and some of its applications.

Since competing in 2000, Feng has helped develop bacterial tools for gene editing and diagnostics. One of the really exciting advances over the past decade-plus has been the completion of the human genome, he said. By using genomics, scientists are now rapidly learning about what causes health problems and what can potentially be used as a way to treat illnesses.

Out of its many uses, CRISPRs potential as a therapeutic is most tantalizing to researchers and the public, but Feng cautioned against hasty adoption. One of the ongoing challenges, especially surrounding the development of gene editing and more broadly, biotechnology, is to also think about bioethics. STS finalist, Amogh Bhatnagar asked Feng if there should be any governmental regulations for the use of CRISPR. Another finalist, Jake Yasonik, wanted to know if gene-edited babies would become the norm in the future. In acknowledging the complex nature of these questions, Feng stressed the importance of involving the entire scientific community for input. Different groups have different opinions and its really important to have discussions and have all these different groups come up with a consensus for how to go about using the technology.

Ultimately, it will be up to the finalists to have these important conversations. As you go through college and training, you will become leaders in scientific, political, ethical or medical professions. Really think about these issues, Feng encouraged. These are the things that will impact humanity in a very irreversible way going forward.

Based on Fengs conversation with the finalists, it is clear more scientific innovation is possible. Theres so much out there to explore. Its very exciting, he expressed. Were really in a golden age where theres so much data and computational resources. We are beginning to learn so much more about the natural world and we can also try to make something useful out of it. When STS finalist, Alina Pollner, asked about his research experience, Feng had these words of wisdom to share: In science, you will have many eureka moments. Once you have one, you will yearn for another, its almost like getting addicted. Thats really the joy of doing science.

Read the rest here:
CRISPR pioneer and STS alumnus on the "joy of doing science" - Science News for Students

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.)

Craig W. Stevens, Oklahoma State University

(THE CONVERSATION) Even as the COVID-19 pandemic cripples the economy and kills hundreds of people each day, there is another epidemic that continues to kill tens of thousands of people each year through opioid drug overdose.

Opioid analgesic drugs, like morphine and oxycodone, are the classic double-edged swords. They are the very best drugs to stop severe pain but also the class of drugs most likely to kill the person taking them. In a recent journal article, I outlined how a combination of state-of-the-art molecular techniques, such as CRISPR gene editing and brain microinjection methods, could be used to blunt one edge of the sword and make opioid drugs safer.

I am a pharmacologist interested in the way opioid drugs such as morphine and fentanyl can blunt pain. I became fascinated in biology at the time when endorphins natural opioids made by our bodies were discovered. I have been intrigued by the way opioid drugs work and their targets in the brain, the opioid receptors, for the last 30 years. In my paper, I propose a way to prevent opioid overdoses by modifying an opioid users brain cells using advanced technology.

Opioid receptors stop breathing

Opioids kill by stopping a person from breathing (respiratory depression). They do so by acting on a specific set of respiratory nerves, or neurons, found in the lower part of the brain that contain opioid receptors. Opioid receptors are proteins that bind morphine, heroin and other opioid drugs. The binding of an opioid to its receptor triggers a reaction in neurons that reduces their activity. Opioid receptors on pain neurons mediate the pain-killing, or analgesic, effects of opioids. When opioids bind to opioid receptors on respiratory neurons, they slow breathing or, in the case of an opioid overdose, stop it entirely.

Respiratory neurons are located in the brainstem, the tail-end part of the brain that continues into the spine as the spinal cord. Animal studies show that opioid receptors on respiratory neurons are responsible for opioid-induced respiratory depression the cause of opioid overdose. Genetically altered mice born without opioid receptors do not die from large doses of morphine unlike mice with these receptors present.

Unlike laboratory mice, humans cannot be altered when embryos to remove all opioid receptors from the brain and elsewhere. Nor would it be a good idea. Humans need opioid receptors to serve as the targets for our natural opioid substances, the endorphins, which are released into the brain during times of high stress and pain.

Also, a total opioid receptor knockout in humans would leave that person unresponsive to the beneficial pain-killing effects of opioids. In my journal article, I argue that what is needed is a selective receptor removal of the opioid receptors on respiratory neurons. Having reviewed the available technology, I believe this can be done by combining CRISPR gene editing and a new neurosurgical microinjection technique.

CRISPR to the rescue: Destroying opioid receptors

CRISPR, which is an acronym for clustered regularly interspaced short palindromic repeats, is a gene editing method that was discovered in the genome of bacteria. Bacteria get infected by viruses too and CRISPR is a strategy that bacteria evolved to cut-up the viral genes and kill invading pathogens.

The CRISPR method allows researchers to target specific genes expressed in cell lines, tissues, or whole organisms, to be cut-up and removed knocked out or otherwise altered. There is a commercially available CRISPR kit which knocks out human opioid receptors produced in cells that are grown in cell cultures in the lab. While this CRISPR kit is formulated for in vitro use, similar conditional opioid receptor knock-out techniques have been demonstrated in live mice.

To knockout opioid receptors in human respiratory neurons, a sterile solution containing CRISPR gene-editing molecules would be prepared in the laboratory. Besides the gene-editing components, the solution contains chemical reagents that allow the gene-editing machinery to enter the respiratory neurons and make their way into the nucleus and into the neurons genome.

How does one get the CRISPR opioid receptor knockout solution into a persons respiratory neurons?

Enter the intracranial microinjection instrument (IMI) developed by Miles Cunningham and his colleagues at Harvard. The IMI allows for computer-controlled delivery of small volumes of solution at specific places in the brain by using an extremely thin tube about twice the diameter of a human hair that can enter the brain at the base of the skull and thread through brain tissue without damage.

The computer can direct the robotic placement of the tube as it is fed images of the brain taken before the procedure using MRI. But even better, the IMI also has a recording wire embedded in the tube that allows measurement of neuronal activity to identify the right group of nerve cells.

Because the brain itself feels no pain, the procedure could be done in a conscious patient using only local anesthetics to numb the skin. Respiratory neurons drive the breathing muscles by firing action potentials which are measured by the recording wire in the tube. When the activity of the respiratory neurons matches the breathing movements by the patients, the proper location of the tube is confirmed and the CRISPR solution injected.

The call for drastic action

Opioid receptors on neurons in the brain have a half-life of about 45 minutes. Over a period of several hours, the opioid receptors on respiratory neurons would degrade and the CRISPR gene-editing machinery embedded in the genome would prevent new opioid receptors from appearing. If this works, the patient would be protected from opioid overdose within 24 hours. Because the respiratory neurons do not replenish, the CRISPR opioid receptor knockout should last for life.

With no opioid receptors on respiratory neurons, the opioid user cannot die from opioid overdose. After proper backing from National Institute on Drug Abuse and leading research and health care institutions, I believe CRISPR treatment could enter clinical trials in between five to 10 years. The total cost of opioid-involved overdose deaths is about US$430 billion per year. CRISPR treatment of only 10% of high-risk opioid users in one year would save thousands of lives and $43 billion.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

Intracranial microinjection of CRISPR solutions might seem drastic. But drastic actions that are needed to save human lives from opioid overdoses. A large segment of the opioid overdose victims are chronic pain patients. It may be possible that chronic pain patients in a terminal phase of their lives and in hospice care would volunteer in phase I clinical trials for the CRISPR opioid receptor knockout treatment I propose here.

Making the opioid user impervious to death by opioids is a permanent solution to a horrendous problem that has resisted efforts by prevention, treatment and pharmacological means. Steady and well-funded work to prove the CRISPR method, first with preclinical animal models then in clinical trials, is a moonshot for the present generation of biomedical scientists.

This article is republished from The Conversation under a Creative Commons license. Read the original article here: https://theconversation.com/how-gene-editing-a-persons-brain-cells-could-be-used-to-curb-the-opioid-epidemic-143165.

Go here to read the rest:
How gene editing a person's brain cells could be used to curb the opioid epidemic - Thehour.com

Image: Mammoths CRISPR-based Covid test (Photo courtesy of Mammoth Biosciences)

The award will help scale Mammoths CRISPR-based DETECTR test onto high-throughput automated platforms in commercial labs for COVID-19 diagnostics at an accelerated rate, increasing access to accurate tests with faster turnaround across the US. Mammoths SARS-CoV-2 DETECTRTM assay uses CRISPR technology, which provides a simpler workflow and significantly faster turnaround time compared to conventional PCR methods.

With a USD 1.5 billion investment from federal stimulus funding, the RADx initiative infuses funding into early innovative technologies to speed development of rapid and widely accessible COVID-19 testing. The Rapid Acceleration of Diagnostics Tech (RADx Tech) program specifically aims to support the development and commercialization of innovative technologies to significantly increase the US testing capacity for SARS-CoV-2. With the support of the RADx program, Mammoth will scale the manufacturing of its proprietary DETECTR platform to provide a high-throughput, sample-to-answer turnkey solution for commercial laboratories to enable a multi-fold increase in testing capacity.

CRISPR has the potential to help curb the COVID-19 pandemic and relieve the testing shortage, said Trevor Martin, Ph.D., co-founder and CEO of Mammoth Biosciences. We are honored to receive this support for our CRISPR-based platform to bring high-throughput, accurate testing to more people, at a time when its needed most.

This is an exciting milestone, said Bruce Tromberg, Ph.D., Director of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) and leader of RADx Tech, one of four components of the NIH RADx initiative. It will help increase US testing capacity exponentially. Game-changing technologies emerging from our RADx pipeline will inform public health measures to stop the spread of the virus and leave us better equipped to address future pathogens and other diseases.

Related Links:Mammoth Biosciences

The rest is here:
Mammoth Biosciences' CRISPR SARS-CoV-2 Diagnostic Platform Becomes First CRISPR-Based Initiative to Be Funded by NIH - HospiMedica

ZUG, Switzerland and CAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate virtually in the following investor conferences in August:

William Blair Biotech Focus ConferenceDate: Thursday, August 6, 2020Panel: 1:00 p.m. ET

Canaccord Genuity 40th Annual Growth ConferenceDate: Thursday, August 13, 2020Fireside chat: 2:30 p.m. ET

A live webcast of these events will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit http://www.crisprtx.com.

Investor Contact:Susan Kim+1-617-307-7503susan.kim@crisprtx.com

Media Contact:Rachel Eides WCG on behalf of CRISPR+1-617-337-4167reides@wcgworld.com

Read the original here:
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - Yahoo Finance

Written by Abhishek De, Edited by Explained Desk | New Delhi | Updated: August 5, 2020 9:45:10 am Covid-19 testing types, process: A member of the Brooklyn Hospital Center COVID-19 testing team calls in the next patient in line in the Brooklyn borough of New York (AP)

With experts predicting the demand for Covid-19 tests in the US to be millions more per day above current levels in the coming weeks, the government has awarded contracts worth $248.7 million to seven biomedical firms to produce next-generation tests under its Rapid Acceleration of Diagnostics (RADx) initiative.

The aim behind the initiative is to significantly increase the number, type and availability of tests by millions per week by fall. According to the National Institutes of Health (NIH), the seven firms have already received Emergency Use Authorisation from the US Food and Drug Authority (FDA) after they were found successful in the first phase of trials.

While one test uses the gene-editing technique called CRISPR to spot SARS-CoV-2, another uses a technique for scanning the genetic code to see if someone has contracted the virus. Another uses saliva samples rather than time-consuming swab tests while a fourth uses a hand-held device that produces results within 30 minutes.

The development comes even as the US reported the biggest number of new cases of any month in July since the pandemic began, with more than 1.9 million new cases, according to data from Johns Hopkins University.

The NIH launched the RADx programme on April 29 days after receiving an emergency appropriation of $1.5 billion from Congress to support innovative technologies to make millions of rapid Covid-19 tests. The seven firms were chosen from over 650 applicants and 31 projects.

While the US has conducted more Covid-19 tests than any other country, more than 60 million, there have been reports that Americans still continue to wait in queues to get tested and results get delayed by weeks. The RADx initiative will help develop new tests that will allow students, teachers and other workers to get tested frequently, allowing the safe re-opening of educational institutions and bringing back normal economic activity. The initiative is aiming at approximately 6 million daily tests in the United States by December.

Mesa Biotech: The company has developed a test that employs a hand-held RT-PCR device and a compact, single-use cartridge that detects viral RNA at the point of care. Named Accula SARS-CoV-2 test, one can see the results from the removable cartridge in 30 minutes.

Quidel: This is also a point-of-care test and has been identified for use in nursing homes or pharmacies. Named Quidel Sofia SARS Antigen FIA test, a lateral flow immunoassay, it uses analysers equipped with advanced fluorescence detection with an ultraviolet LED energy source. The analysers give results within 15 minutes.

Talis Biomedical: Capable of returning a result under 30 minutes, the Talis One Covid-19 test uses a multiplexed cartridge to detect SARS-CoV-2 through isothermal amplification of viral RNA and an optical detection system.

Express Explainedis now onTelegram. Clickhere to join our channel (@ieexplained)and stay updated with the latest

Ginkgo Bioworks: The Boston-based firm uses next-generation sequencing technologies to process tens of thousands of individual tests at once and will provide end-to-end sample collection and report results within 24-48 hours. The company is expected scale up to 50,000 tests per day in September and 100,000 per day by the end of the year.

Helix OpCo: The Covid-19 test by Helix uses nasal swabs to collect samples that can be processed in very volumes at once and can give results within 24-48 hours using a combination of sophisticated automation processes.

Fluidigm: The California-based firm has developed a diagnostic molecular test integrated with fluidic chips that detects SARS-CoV-2 from saliva specimens. The high-throughput test, named Advanta Dx SARS-CoV-2 RT-PCR Assay, does not need a viral RNA extraction kit.

Mammoth Biosciences Inc: The Covid-19 test, named SARS-CoV-2 DETECTR assay, uses gene-editing CRISPR technology, which provides a simpler workflow and faster turnaround time compared to conventional PCR tests.

The CRISPR technology can detect even a small extract of SARS-CoV-2 genetic material in a nose, mouth or throat swab, or in fluid from the lungs. If the viruss genetic material is detected, the CRISPR enzyme generates a fluorescent glow.

The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest Explained News, download Indian Express App.

IE Online Media Services Pvt Ltd

See the original post:
Explained: The new and quicker Covid-19 tests approved under the US RADx scheme - The Indian Express

Dublin, Aug. 04, 2020 (GLOBE NEWSWIRE) -- The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report ScopeThe report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/8msd9m

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

See more here:
CRISPR Technology Market to Grow by 20.91% in 2020, Accelerated by the Outbreak of COVID-19 - Industry Projections to 2030 - GlobeNewswire

DUBLIN--(BUSINESS WIRE)--The "CRISPR Technology Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to ResearchAndMarkets.com's offering.

Where is the largest and fastest growing market for the crispr technology market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This global market report answers all these questions and many more.

The global CRISPR technology market is expected to increase from $0.76 billion in 2019 to $0.92 billion in 2020 at a compound annual growth rate (CAGR) of 20.91%. The exponential growth is mainly due to the COVID-19 outbreak that has led to the research for drugs for COVID-19 with gene-editing using CRISPR technology. The market is expected to reach $1.55 billion in 2023 at a CAGR of 19.13%.

The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc's Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services.

North America was the largest region in the CRISPR technology market in 2019. Europe was the second-largest region in the CRISPR technology market in 2019.

Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. Several advancements in CRISPR technology are trending in the market during the period.

Major players in the CRISPR technology market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery plc, Integrated DNA Technologies, Inc. (Danaher), Origene Technologies, Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc., and GeneCopoeia, Inc.

Report Scope

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography. It places the market within the context of the wider crispr technology market, and compares it with other markets.

Companies Mentioned (A-Z)

For more information about this report visit https://www.researchandmarkets.com/r/71fzdf

Read the original here:
Global CRISPR Technology Market Outlook 2020-2030 - Industry Driven by CRISPR Technology Being Used as a Diagnostic Tool for COVID-19 -...

Global CRISPR gene-editing market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of the CRISPR gene-editing market for Global, Europe, North America, Asia-Pacific, South America, and the Middle East & Africa.

Global CRISPR Gene-Editing Market report performs systematic gathering, recording and analysis of data about the issues related to the marketing of goods and services and serves the businesses with an excellent market research report. The report provides intelligent solutions to complex business challenges and commences an effortless decision-making process. The report analyses and evaluates the important industry trends, market size, market share estimates, and sales volume with which industry can speculate the strategies to increase return on investment (ROI). In the Global CRISPR Gene-Editing Market document, the statistics have been represented in the graphical format for an unambiguous understanding of facts and figures.

CRISPR gene-editing marketis rising gradually with a healthy CAGR of 23.35 % in the forecast period of 2019-2026. Growing prevalence of cancer worldwide and expanding the application of CRISPR technology by innovative research from the different academic organizations are the key factors for market growth.

Get a Sample Copy of the Report @ (Use Corporate email ID to Get Higher Priority) @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-crispr-gene-editing-market

Key Market Players:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

Market Dynamics:

Set of qualitative information that includes PESTEL Analysis, PORTER Five Forces Model, Value Chain Analysis and Macro Economic factors, Regulatory Framework along with Industry Background and Overview.

Global CRISPR Gene-Editing Market By Therapeutic Application (Oncology, Autoimmune/Inflammatory), Application (Genome Engineering, Disease Models, Functional Genomics and Others), Technology (CRISPR/Cas9, Zinc Finger Nucleases and Others), Services (Design Tools, Plasmid and Vector, Cas9 and g-RNA, Delivery System Products and Others), Products (GenCrispr/Cas9 kits, GenCrispr Cas9 Antibodies, GenCrispr Cas9 Enzymes and Others), End-Users (Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes, Contract Research Organizations and Others), Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2026

Global CRISPR Gene-Editing Research Methodology

Data Bridge Market Research presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers.

Major Drivers and Restraints of the CRISPR Gene-Editing Industry

High prevalence of cancer worldwide is driving the growth of this marketJoint ventures by biotechnical companies for the advancement of genetic engineering for the development of CRISPR worldwide can also boost the market growthExpanding the application of CRISPR technology by innovative research from the different academic organizations also enhances the market growth

High finance in research and development also acts as a driving factor in the growth of this marketProbable mistreatment of CRISPR gene editing device and CRISPR/Cas genome editing device is restricting the growth for the marketScientific and major technical challenges for the production of disease specific novel CRISPR gene editing can also hamper the market growthLack of healthcare budget in some middle-income countries restricts the market growth

Complete report is available (TOC) @https://www.databridgemarketresearch.com/toc/?dbmr=global-crispr-gene-editing-market

The titled segments and sub-section of the market are illuminated below:

By Therapeutic

OncologyAutoimmune/Inflammatory

By Application

Genome EngineeringDisease ModelsFunctional GenomicsOthers

By Technology

CRISPR/Cas9Zinc Finger NucleasesOthers

By Services

Design ToolsPlasmid and VectorCas9 and g-RNADelivery System ProductsOthers

By Products

GenCrispr/Cas9 kitsGenCrispr Cas9 AntibodiesGenCrispr Cas9 EnzymesOthers

By End-Users

Biotechnology & Pharmaceutical CompaniesAcademic & Government Research InstitutesContract Research OrganizationsOthers

Top Players in the Market are:

Few of the major competitors currently working in the global CRISPR gene-editing market are Applied StemCell, ACEA BIO, Synthego, Thermo Fisher Scientific Inc, GenScript, Addgene, Merck KGaA, Intellia Therapeutics, Inc, Cellectis, Precision Biosciences, Caribou Biosciences, Inc, Transposagen Biopharmaceuticals, Inc, OriGene Technologies, Inc, Novartis AG, New England Biolabs among others

How will the report help new companies to plan their investments in the CRISPR Gene-Editing market?

The CRISPR Gene-Editing market research report classifies the competitive spectrum of this industry in elaborate detail. The study claims that the competitive reach spans the companies.

The report also mentions about the details such as the overall remuneration, product sales figures, pricing trends, gross margins, etc.

Information about the sales & distribution area alongside the details of the company, such as company overview, buyer portfolio, product specifications, etc., are provided in the study.

Any query? Enquire Here For Discount Or Report Customization: @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-crispr-gene-editing-market

Some of the Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Definition and forecast parameters

Methodology and forecast parameters

Data Sources

Chapter 2: Executive Summary

Business trends

Regional trends

Product trends

End-use trends

Chapter 3: CRISPR Gene-Editing Industry Insights

Industry segmentation

Industry landscape

Vendor matrix

Technological and innovation landscape

Chapter 4: CRISPR Gene-Editing Market, By Region

Chapter 5: Company Profile

Business Overview

Financial Data

Product Landscape

Strategic Outlook

SWOT Analysis

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Follow this link:
Global CRISPR Gene-Editing Market Future Growth Analysis, Business Demand and Opportunities to 2027 | Applied StemCell, ACEA BIO, Synthego, Thermo...

The global CRISPR and Cas Genes Market Report 2020 was prepared to provide the market landscape and unlimited guidelines for the current market size, market share, driving factors, Trends, progressive growth and the dominant players of the CRISPR and Cas Genes Market . The report provides top manufacturers, distributors, dealers and dealers with general information about the market. It will help you to understand the product scope, the market overview, the driving force of the market, technological progress, market risk, opportunities and research results.

Market Report world has monitored the CRISPR and Cas Genes Market for the new Research Areas industrial market CRISPR and Cas Genes Market was valued at USD 1.35 Billion in 2019 and is projected to reach USD 4.53 Billion by 2027, growing at a CAGR of 16.36 % from 2020 to 2027.

Our Reports on the CRISPR and Cas Genes Market for the new Research Areas industrial market offer a holistic analysis, market size and forecast, Trends, growth drivers and challenges as well as a supplier analysis for about 25 suppliers.

To request an exclusive sample report for CRISPR and Cas Genes Market : https://www.verifiedmarketresearch.com/download-sample/?rid=40530&utm_source=PFS&utm_medium=001

Global CRISPR and Cas Genes Market research to 2020 provides a basic Overview of the industry including definitions, classifications, applications and structure of the industrial chain. The global CRISPR and Cas Genes Market report is provided for international markets as well as for development trends, competitive landscape analyses and the development status of key regions. Development policies and plans are discussed and manufacturing processes and cost structures analyzed. This report also includes information on import / Export consumption, supply and demand, costs, Price, Sales and gross margins.

COVID-19 can influence the global economy in three ways: by directly influencing production and demand, by creating supply chain and market disruptions, and by having a financial impact on businesses and financial markets. The eruption of COVID-19 has implications for many aspects such as flight cancellations. Travel bans and quarantines; Restaurants closed; all Indoor Events restricted; over forty countries declared a state of emergency; massive supply chain slowdown; stock market volatility; falling business confidence, growing panic in the population and uncertainty about the future.

This report examines the global CRISPR and Cas Genes Market and analyses and examines the IoT in Education development status and forecast in the US, EU, Japan, China, India and Southeast Asia. This report focuses on the highest players in the global CRISPR and Cas Genes Market .

Ask For Discount @https://www.verifiedmarketresearch.com/ask-for-discount/?rid=40530&utm_source=PFS&utm_medium=001

The scope of the report covers all major system technologies currently being implemented in the global IoT in Education industry. Market values are supported the Top User (public and private) supports the production of IoT in Education systems. CRISPR and Cas Genes Market manufacturers place orders as soon as they receive work orders from CRISPR and Cas Genes Market operators. Therefore, market figures are derived from the perspective of the top users taking into account their orders (CRISPR and Cas Genes Market operator) for the CRISPR and Cas Genes Market .

North America (USA, Canada and Mexico)

Europe (Germany, Great Britain, France, Italy, Russia and Turkey etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia and Vietnam))

-South America (Brazil, etc.)

The Middle East and Africa (North Africa and GCC countries)

The CRISPR and Cas Genes Market was created on the basis of an in-depth market analysis with contributions from industry experts. The report covers the growth prospects in the coming years and the discussion of the main providers.

Market drivers

Increasing deforestation due to increasing demand for increasing raw materials

For a full, detailed list, see our report

Market Challenge

Risks associated with the use of IoT in Education

For a full, detailed list, see our report

Market Trend

Increasing consumer preference for IoT in EducationFor a full, detailed list, see our report

The global market research report of IoT in Education industry 2020 is distributed over several pages and contains exclusive Statistics, data, information, CRISPR and Cas Genes Market trends and details of the competitive landscape in this niche sector.

To understand how the effects of COVID-19 are addressed in this report. A sample copy of the report is available at https://www.verifiedmarketresearch.com/product/crispr-and-cas-genes-market/?utm_source=PFS&utm_medium=001

-To analyze IoT in Education consumption (value and volume), product type and Application, History data from 2015 to 2020 and forecast.

-To understand the structure of the CRISPR and Cas Genes Market , identify the different sub-segments.

Focuses on the most important IoT in Education manufacturers to define, describe and analyze sales volume, value, market share, market competition landscape, STREBER analysis and development plans in the coming years.

To analyze the CRISPR and Cas Genes Market taking into account individual growth trends, future prospects and their contribution to the overall market

Detailed information on the key factors influencing the Expansion of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To analyze competitive developments such as extensions, agreements, product launches and acquisitions within the company

To strategically profile the main players and to comprehensively analyse their growth strategies.

The report also focuses on the worlds leading industry players in the global CRISPR and Cas Genes Market , providing information such as company profiles, product images and specifications, capacity, production, price, cost, revenue and contacting information. In addition, upstream raw materials and equipment as well as downstream demand analyses are managed. The global CRISPR and Cas Genes Market development trends and market channels are analyzed. Finally, the feasibility of the latest investment projects is evaluated and general research results are offered. With tables and figures to help analyze the global CRISPR and Cas Genes Market , this study provides important statistics on the state of the industry and can be a valuable guide and guidance for companies and individuals who are curious about the market.

This report provides a pinpoint analysis of the change in competitive dynamics

CRISPR and Cas Genes Market provides a forward-looking perspective on various factors that drive or inhibit market growth.

It includes a six-year forecast, which is assessed on the basis of expected market growth

Better understanding of the effects of specific conditions on the prevailing population of the CRISPR and Cas Genes Market .

To understand the most important product segments and their future

Transfer of more accurate information for clinical trials to determine research size and realistic recruitment for different countries

CRISPR and Cas Genes Market helps with sound business decisions by having complete insights into the market and analyzing market segments in depth

-To provide distinctive graphics and exemplary STREBER analysis of the most important market segments

Verified Market Researchis a leading Global Research and Consulting firm servicing over 5000+ customers. Verified Market Research provides advanced analytical research solutions while offering information enriched research studies. We offer insight into strategic and growth analyses, Data necessary to achieve corporate goals, and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance use industrial techniques to collect and analyze data on more than 15,000 high impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (203)-411-9686APAC: +91 (902)-863-5784US Toll-Free: +1 (800)-7821768

Email:[emailprotected]

More here:
CRISPR and Cas Genes Market Size, Historical Growth, Analysis, Opportunities and Forecast To 2027 - Owned

A recently published market research report by Fact.MR on the CRISPR and Cas Genes Market depicts a crystal clear view of the market over the considered period of assessment (2020 2026). The global CRISPR and cas genes market study comes with an all in all compilation of the future, existing, and historical outlook of the market as well as the factors bringing in such growth for the market. With SWOT analysis, the business study highlights the strengths, weaknesses, opportunities, and threats of each CRISPR and cas genes market player in a comprehensive way. Further, the CRISPR and cas genes market report emphasizes the adoption pattern of the CRISPR and cas genes across various industries.

The existing trends, restraints, opportunities, and market drivers are studied thoroughly to offer a clear, 360-degree understanding of the existing landscape prevailing in the CRISPR and cas genes market. The research paints a detailed picture of how the market is likely to take shape in the coming years given the influence of current drivers, opportunities, and restraints. In this latest market research study published by Fact.MR, the analysts have taken into account the CRISPR and cas genes market from a local as well as global viewpoint.

Act Today to Succeed Tomorrow, Know the COVID-19 Impact, Request for Sample @https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

The outbreak of novel coronavirus across the globe has changed the way about how we do business, it has resulted in both disadvantages and advantages for players operating in the CRISPR and cas genes market. A health crisis of enormous proportion, COVID-19 has emerged as a pandemic that would cause a restructuring of the world economy as well as social order. This outbreak is clearly going to characterize the coming era with fundamental schism. Many companies have shifted from their traditional methods of advertising during the lockdown period.

Taking help of this latest offering on the CRISPR and cas genes market by Fact.MR, the market players, suppliers, distributors, and other stakeholders can formulate innovative strategies based on their understanding of the pandemic and our report to expand their business and widen their base of customers. This research study by Fact.MR is likely to detail the factors that could impact the sales of products/ services in the global market landscape. The report is also likely to suggest avenues of growth that could boost sales in the post-pandemic era.

According to the market research report, the CRISPR and cas genes market is estimated to register a CAGR growth of 21.2% over the assessment period due to several key factors that is likely to influence the market, such as favorable regulatory policies, augmented spending on research and development. The analysts at Fact.MR makes use of the latest research methodologies while gathering data from credible and reliable sources, both primary and secondary, to prepare and present the market study.

In this CRISPR and cas genes market study, the following years are considered to project the market footprint:

The CRISPR and cas genes market report has answers to important questions, which include the following:

The CRISPR and cas genes market report covers the following regions:

On the basis of product type, the CRISPR and cas genes market report considers the following segments:

On the basis of end-use, the CRISPR and cas genes market report includes:

Ask for Regional Data of This Report @ https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Prominent CRISPR and cas genes market players covered in the report contain:

The behavioral pattern of each of the market player, such as acquisitions, new product launches, partnerships, and mergers have been thoroughly studied to offer a detailed view of the competitive landscape of the CRISPR and cas genes market.

Contact:

Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,

Jumeirah Lakes Towers, Dubai, United Arab Emirates

MARKET ACCESS DMCC Initiative

Email: sales@factmr.com

Web: https://www.factmr.com/

See the rest here:
Scaling the COVID-19 Impact: Fact.MR Projects Staggering Growth in CRISPR and Cas Genes Market 2020 2026 - The Cloud Tribune

IndustryGrowthInsights (IGI) offers a detailed report on Global CRISPR Genome Editing Market. The report is a comprehensive research study that provides the scope of CRISPR Genome Editing market size, industry growth opportunities and challenges, current market trends, potential players, and expected performance of the market in regions for the forecast period from 2020 to 2026. This report highlights key insights on the market focusing on the possible requirements of the clients and assisting them to make right decision about their business investment plans and strategies.

The CRISPR Genome Editing market report also covers an overview of the segments and sub-segmentations including the product types, applications, companies and regions. This report further includes the impact of COVID-19 on the market and explains dynamics of the market, future business impact, competition landscape of the companies, and the flow of the global supply and consumption. The report provides an in-depth analysis of the overall market structure of CRISPR Genome Editing and assesses the possible changes in the current as well as future competitive scenarios of the CRISPR Genome Editing market.

Request a sample before buying this report @ https://industrygrowthinsights.com/request-sample/?reportId=136905

The published report consists of a robust research methodology by relying on primary source including interviews of the company executives & representatives and accessing official documents, websites, and press release of the companies. IndustryGrowthInsights (IGI) is known for its data accuracy and granular market reports.

The report is prepared with a group of graphical representations, tables, and figures which displays a clear picture of the developments of the products and its market performance over the last few years. With this precise report, it can be easily understood the growth potential, revenue growth, product range, and pricing factors related to the CRISPR Genome Editing market. The report also covers the recent agreements including merger & acquisition, partnership or joint venture and latest developments of the manufacturers to sustain in the global competition of the CRISPR Genome Editing market.

Key companies that are covered in this report:

Editas MedicineCRISPR TherapeuticsHorizon DiscoverySigma-AldrichGenscriptSangamo BiosciencesLonza GroupIntegrated DNA TechnologiesNew England BiolabsOrigene TechnologiesTransposagen BiopharmaceuticalsThermo Fisher ScientificCaribou BiosciencesPrecision BiosciencesCellectisIntellia Therapeutics

*Note: Additional companies can be included on request

The report covers a detailed performance of some of the key players and analysis of major players in the industry, segments, application, and regions. Moreover, the report also considers the governments policies in different regions which illustrates the key opportunities as well as challenges of the market in each region.

By Application:

Biotechnology CompaniesPharmaceutical CompaniesOthers

By Type:

Genetic EngineeringGene LibraryHuman Stem CellsOthers

As per the report, the CRISPR Genome Editing market is projected to reach a value of USDXX by the end of 2026 and grow at a CAGR of XX% through the forecast period (2020-2026). The report describes the current market trend of the CRISPR Genome Editing in regions, covering North America, Latin America, Europe, Asia Pacific, and Middle East & Africa by focusing the market performance by the key countries in the respective regions. According to the need of the clients, this report can be customized and available in a separate report for the specific region.

You can also go for a yearly subscription of all the updates on CRISPR Genome Editing market.

You can buy the complete report @ https://industrygrowthinsights.com/checkout/?reportId=136905

The following is the TOC of the report:

Executive Summary

Assumptions and Acronyms Used

Research Methodology

CRISPR Genome Editing Market Overview

Global CRISPR Genome Editing Market Analysis and Forecast by Type

Global CRISPR Genome Editing Market Analysis and Forecast by Application

Global CRISPR Genome Editing Market Analysis and Forecast by Sales Channel

Global CRISPR Genome Editing Market Analysis and Forecast by Region

North America CRISPR Genome Editing Market Analysis and Forecast

Latin America CRISPR Genome Editing Market Analysis and Forecast

Europe CRISPR Genome Editing Market Analysis and Forecast

Asia Pacific CRISPR Genome Editing Market Analysis and Forecast

Asia Pacific CRISPR Genome Editing Market Size and Volume Forecast by Application

Middle East & Africa CRISPR Genome Editing Market Analysis and Forecast

Competition Landscape

Why you should buy this report?

This report offers a concise analysis of the CRISPR Genome Editing market for the last 5 years with historical data & more accurate prediction for upcoming 6 years on the basis of statistical information.

This report helps you to understand the market components by offering a cohesive framework of the key players and their competition dynamics as well as strategies.

The report is a complete guideline for the clients to arrive an informed business decision since it consists of a detailed information for better understandings of the current & future market situation.

The report also answers some of the key questions given below:

Which end-user is likely to play a crucial role in the development of the CRISPR Genome Editing market?

Which regional market is expected to dominate the CRISPR Genome Editing market in 2020-2026?

How is consumer consumption behavior impacting the business operations of market players in the current scenario of the CRISPR Genome Editing market?

If you have any questions on this report, please reach out to us @ https://industrygrowthinsights.com/enquiry-before-buying/?reportId=136905

About IndustryGrowthInsights (IGI):

We possess expertise in a variety of business intelligence domains. Our key analysis segments, though not restricted to the same, include market entry strategies, market size estimations, market trend analysis, market opportunity analysis, market threat analysis, market growth/fall forecasting, primary interviews, secondary research & consumer surveys.

We invest in our analysts to ensure that we have a full roster of experience and expertise in any field we cover. Our team members are selected for stellar academic records, specializations in technical fields, and exceptional analytical and communication skills. We also provide ongoing training and knowledge sharing to keep our analysts tapped into industry best practices.

Contact Info: Name: Alex MathewsAddress: 500 East E Street, Ontario,CA 91764, United States.Phone No: USA: +1 909 545 6473 | IND: +91-7000061386Email: [emailprotected]Website: https://industrygrowthinsights.com

See original here:
CRISPR Genome Editing Market To 2026: Growth Analysis By Manufacturers, Regions, Types And Applications - Market Research Vista

Global CRISPR Industry market Report 2020 presents critical information and factual data about the CRISPR Industry market, providing an overall statistical study of this market on the basis of market drivers, market limitations, and its future prospects. The widespread CRISPR Industry market opportunities and trends are also taken into consideration in CRISPR Industry industry. with growth trends, various stakeholders like investors, traders, suppliers, SWOT analysis Opportunities and Threat to the organization and others.

The CRISPR Industry market report comprises of the key trends which influence the industry growth with respect to the regional terrain and competitive arena. The study highlights the opportunities that will support the industry expansion in existing and untapped markets along with the challenges the business sphere will face. Besides this, the report also offers an intricate analysis of case studies including those of COVID-19 pandemic, with the aim to provide a clear picture of this industry vertical to all shareholders.

Pivotal pointers from COVID-19 impact assessment:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/158192

Analysis of the regional terrain:

Highlights of the CRISPR Industry market report:

Key Coverage of report:

Impact of the latest technological innovations on the CRISPR Industry market

Key growth strategies adopted by the prominent market players to address the challenges and restraints put forward by the COVID-19 pandemic

Historical and current trends likely to affect the overall market dynamics of the CRISPR Industry market

Growth assessment of the various market segments over the forecast timeline

Regional and global presence of major market players in the CRISPR Industry market

Table of Content:

1 CRISPR Industry market Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of CRISPR Industry market

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the CRISPR Industry industry

1.4 Methodology of The Study

1.5 Research Data Source

2 Executive Summary

2.1 Market Overview

2.1.1 Global CRISPR Industry market Size, 2015 - 2020

2.1.2 Global CRISPR Industry market Size by Type, 2015 - 2020

2.1.3 Global CRISPR Industry market Size by Application, 2015 - 2020

2.1.4 Global CRISPR Industry market Size by Region, 2015 - 2025

2.2 Business Environment Analysis

2.2.1 Global COVID-19 Status and Economic Overview

2.2.2 Influence of COVID-19 Outbreak on CRISPR Industry Industry Development

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/158192

Original post:
Global CRISPR Market Potential Growth, Share, Demand and Analysis of Key Players- Research Forecasts to 2025 - Express Journal

CRISPR And CRISPR-Associated (Cas) Genes Market report tracks the data since 2015 and is one of the most detailed reports. It also contains data varying according to region and country. The insights in the report are easy to understand and include pictorial representations.

Get Free Sample PDF Copy of CRISPR And CRISPR-Associated (Cas) Genes Market with Figures, Graphs and Tocs:www.reportsnreports.com/contactme=2846167

The report also includes the impact of ongoing global crisis i.e.COVID-19on the CRISPR And CRISPR-Associated (Cas) Genes Market and what the future holds for it.

The published report is designed using a vigorous and thorough research methodology andReportsnReportsis also known for its data accuracy and granular market reports.

Summary

Market OverviewThe global CRISPR And CRISPR-Associated (Cas) Genes market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of 38.3% in the forecast period of 2020 to 2025 and will expected to reach USD 2685.5 million by 2025, from USD 734.5 million in 2019.The CRISPR And CRISPR-Associated (Cas) Genes market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market segmentationCRISPR And CRISPR-Associated (Cas) Genes market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value.

This analysis can help you expand your business by targeting qualified niche markets.By Type, CRISPR And CRISPR-Associated (Cas) Genes market has been segmented into Genome Editing, Genetic engineering, gRNA Database/Gene Librar, CRISPR Plasmid, Human Stem Cells, Genetically Modified Organisms/Crops, Cell Line Engineering,.By Application, CRISPR And CRISPR-Associated (Cas) Genes has been segmented into Biotechnology Companies, Pharmaceutical Companies, Academic Institutes, Research and Development Institutes,.

Regions and Countries Level AnalysisRegional analysis is another highly comprehensive part of the research and analysis study of the global CRISPR And CRISPR-Associated (Cas) Genes market presented in the report. This section sheds light on the sales growth of different regional and country-level CRISPR And CRISPR-Associated (Cas) Genes markets.

For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global CRISPR And CRISPR-Associated (Cas) Genes market.The report offers in-depth assessment of the growth and other aspects of the CRISPR And CRISPR-Associated (Cas) Genes market in important countries (regions), including United States, Canada, Mexico, Germany, France, United Kingdom, Russia, Italy, China, Japan, Korea, India, Southeast Asia, Australia, Brazil and Saudi Arabia,. It also throws light on the progress of key regional CRISPR And CRISPR-Associated (Cas) Genes markets such as North America, Europe, Asia-Pacific, South America and Middle East & Africa.

Competitive Landscape and CRISPR And CRISPR-Associated (Cas) Genes Market Share AnalysisCRISPR And CRISPR-Associated (Cas) Genes competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, CRISPR And CRISPR-Associated (Cas) Genes sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the CRISPR And CRISPR-Associated (Cas) Genes sales, revenue and market share for each player covered in this report.The major players covered in CRISPR And CRISPR-Associated (Cas) Genes are: Caribou Biosciences, Thermo Fisher Scientific, Merck KGaA, Addgene, Takara Bio USA, CRISPR THERAPEUTICS, Intellia Therapeutics, Editas Medicine, Mirus Bio LLC, Horizon Discovery Group, GE Healthcare Dharmacon,. Among other players domestic and global, CRISPR And CRISPR-Associated (Cas) Genes market share data is available for global, North America, Europe, Asia-Pacific, Middle East and Africa and South America separately.

Global Info Research analysts understand competitive strengths and provide competitive analysis for each competitor separately.

The content of the study subjects, includes a total of 15 chapters:Chapter 1, to describe CRISPR And CRISPR-Associated (Cas) Genes product scope, market overview, market opportunities, market driving force and market risks.Chapter 2, to profile the top manufacturers of CRISPR And CRISPR-Associated (Cas) Genes, with price, sales, revenue and global market share of CRISPR And CRISPR-Associated (Cas) Genes in 2018 and 2019.Chapter 3, the CRISPR And CRISPR-Associated (Cas) Genes competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.Chapter 4, the CRISPR And CRISPR-Associated (Cas) Genes breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2015 to 2020.Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2015 to 2020.Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2015 to 2020.Chapter 12, CRISPR And CRISPR-Associated (Cas) Genes market forecast, by regions, type and application, with sales and revenue, from 2020 to 2025.Chapter 13, 14 and 15, to describe CRISPR And CRISPR-Associated (Cas) Genes sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Enquire for More Information CRISPR And CRISPR-Associated (Cas) Genes Market:www.reportsnreports.com/contactme=2846167

The global CRISPR And CRISPR-Associated (Cas) Genes Market is expected to witness a promising growth in the next few years. The rising level of competition among the leading players and the rising focus on the development of new products are likely to offer promising growth opportunities throughout the forecast period.

The research study on the global CRISPR And CRISPR-Associated (Cas) Genes Market offers a detailed overview, highlighting the key aspects that are expected to enhance the growth of the market in the near future. The key segmentation and the competitive landscape of the market have also been mentioned at length in the research study.

This report studies the CRISPR And CRISPR-Associated (Cas) Genes Market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the CRISPR And CRISPR-Associated (Cas) Genes Market by product type and applications/end industries. These details further contain a basic summary of the company, merchant profile, and the product range of the company in question.

The report analyzes data regarding the proceeds accrued, product sales, gross margins, price patterns, and news updates relating to the company.

Full Report available @www.reportsnreports.com/purchasme=2846167

The report helps to identify the main CRISPR And CRISPR-Associated (Cas) Genes Market players. It assists in analyzing CRISPR And CRISPR-Associated (Cas) Genes Market competitive environment, including company overview, company total revenue, market opportunities, value, production sites and facilities, SWOT analysis, product details.

The study also reveals the sales, revenue and market share for each market player included in this report for the period of 2015-2020. It also helps to ascertain the growth drivers and future prospects for the forecast timeline.

Conclusively, this report is a one stop reference point for the industrial stakeholders to get CRISPR And CRISPR-Associated (Cas) Genes Market forecast of till 2025. This report helps to know the estimated market size, market status, future development, growth opportunity, challenges, growth drivers of by analyzing the historical overall data of the considered market segments.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Link:
CRISPR And CRISPR-Associated (Cas) Genes Market analysis and forecast to 2026 investigated in the latest research - WhaTech Technology and Markets...

LOS ANGELES, United States: QY Research has recently published a report, titled Global and China CRISPR-Based Therapeutics Market Size, Status and Forecast 2020-2026. The research report gives the potential headway openings that prevails in the global market. The report is amalgamated depending on research procured from primary and secondary information. The global Global and China CRISPR-Based Therapeutics market is relied upon to develop generously and succeed in volume and value during the predicted time period. Moreover, the report gives nitty gritty data on different manufacturers, region, and products which are important to totally understanding the market.

Key Companies/Manufacturers operating in the global Global and China CRISPR-Based Therapeutics market include: , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Get PDF Sample Copy of the Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) :

https://www.qyresearch.com/sample-form/form/2027764/global-and-china-crispr-based-therapeutics-market

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Global and China CRISPR-Based Therapeutics market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Global Global and China CRISPR-Based Therapeutics Market Segment By Type:

Genome EditingGenetic EngineeringgRNA Database/Gene LibrarCRISPR PlasmidHuman Stem CellsGenetically Modified Organisms/CropsCell Line Engineering CRISPR-Based Therapeutics

Global Global and China CRISPR-Based Therapeutics Market Segment By Application:

Biotechnology CompaniesPharmaceutical CompaniesAcademic InstitutesResearch and Development Institutes Based on

Competitive Landscape

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the global Global and China CRISPR-Based Therapeutics market.

Key companies operating in the global Global and China CRISPR-Based Therapeutics market include , Caribou Biosciences, Addgene, CRISPR THERAPEUTICS, Merck KGaA, Mirus Bio LLC, Editas Medicine, Takara Bio USA, Thermo Fisher Scientific, Horizon Discovery Group, Intellia Therapeutics, GE Healthcare Dharmacon

Key questions answered in the report:

For Discount, Customization in the Report: https://www.qyresearch.com/customize-request/form/2027764/global-and-china-crispr-based-therapeutics-market

TOC

1 Report Overview1.1 Study Scope1.2 Market Analysis by Type1.2.1 Global CRISPR-Based Therapeutics Market Size Growth Rate by Type: 2020 VS 20261.2.2 Genome Editing1.2.3 Genetic Engineering1.2.4 gRNA Database/Gene Librar1.2.5 CRISPR Plasmid1.2.6 Human Stem Cells1.2.7 Genetically Modified Organisms/Crops1.2.8 Cell Line Engineering1.3 Market by Application1.3.1 Global CRISPR-Based Therapeutics Market Share by Application: 2020 VS 20261.3.2 Biotechnology Companies1.3.3 Pharmaceutical Companies1.3.4 Academic Institutes1.3.5 Research and Development Institutes1.4 Study Objectives1.5 Years Considered 2 Global Growth Trends2.1 Global CRISPR-Based Therapeutics Market Perspective (2015-2026)2.2 Global CRISPR-Based Therapeutics Growth Trends by Regions2.2.1 CRISPR-Based Therapeutics Market Size by Regions: 2015 VS 2020 VS 20262.2.2 CRISPR-Based Therapeutics Historic Market Share by Regions (2015-2020)2.2.3 CRISPR-Based Therapeutics Forecasted Market Size by Regions (2021-2026)2.3 Industry Trends and Growth Strategy2.3.1 Market Trends2.3.2 Market Drivers2.3.3 Market Challenges2.3.4 Market Restraints 3 Competition Landscape by Key Players3.1 Global Top CRISPR-Based Therapeutics Players by Market Size3.1.1 Global Top CRISPR-Based Therapeutics Players by Revenue (2015-2020)3.1.2 Global CRISPR-Based Therapeutics Revenue Market Share by Players (2015-2020)3.2 Global CRISPR-Based Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)3.3 Players Covered: Ranking by CRISPR-Based Therapeutics Revenue3.4 Global CRISPR-Based Therapeutics Market Concentration Ratio3.4.1 Global CRISPR-Based Therapeutics Market Concentration Ratio (CR5 and HHI)3.4.2 Global Top 10 and Top 5 Companies by CRISPR-Based Therapeutics Revenue in 20193.5 Key Players CRISPR-Based Therapeutics Area Served3.6 Key Players CRISPR-Based Therapeutics Product Solution and Service3.7 Date of Enter into CRISPR-Based Therapeutics Market3.8 Mergers & Acquisitions, Expansion Plans 4 CRISPR-Based Therapeutics Breakdown Data by Type (2015-2026)4.1 Global CRISPR-Based Therapeutics Historic Market Size by Type (2015-2020)4.2 Global CRISPR-Based Therapeutics Forecasted Market Size by Type (2021-2026) 5 CRISPR-Based Therapeutics Breakdown Data by Application (2015-2026)5.1 Global CRISPR-Based Therapeutics Historic Market Size by Application (2015-2020)5.2 Global CRISPR-Based Therapeutics Forecasted Market Size by Application (2021-2026) 6 North America6.1 North America CRISPR-Based Therapeutics Market Size (2015-2026)6.2 North America CRISPR-Based Therapeutics Market Size by Type (2015-2020)6.3 North America CRISPR-Based Therapeutics Market Size by Application (2015-2020)6.4 North America CRISPR-Based Therapeutics Market Size by Country (2015-2020)6.4.1 United States6.4.2 Canada 7 Europe7.1 Europe CRISPR-Based Therapeutics Market Size (2015-2026)7.2 Europe CRISPR-Based Therapeutics Market Size by Type (2015-2020)7.3 Europe CRISPR-Based Therapeutics Market Size by Application (2015-2020)7.4 Europe CRISPR-Based Therapeutics Market Size by Country (2015-2020)7.4.1 Germany7.4.2 France7.4.3 U.K.7.4.4 Italy7.4.5 Russia7.4.6 Nordic7.4.7 Rest of Europe 8 China8.1 China CRISPR-Based Therapeutics Market Size (2015-2026)8.2 China CRISPR-Based Therapeutics Market Size by Type (2015-2020)8.3 China CRISPR-Based Therapeutics Market Size by Application (2015-2020)8.4 China CRISPR-Based Therapeutics Market Size by Region (2015-2020)8.4.1 China8.4.2 Japan8.4.3 South Korea8.4.4 Southeast Asia8.4.5 India8.4.6 Australia8.4.7 Rest of Asia-Pacific 9 Japan9.1 Japan CRISPR-Based Therapeutics Market Size (2015-2026)9.2 Japan CRISPR-Based Therapeutics Market Size by Type (2015-2020)9.3 Japan CRISPR-Based Therapeutics Market Size by Application (2015-2020)9.4 Japan CRISPR-Based Therapeutics Market Size by Country (2015-2020)9.4.1 Mexico9.4.2 Brazil 10 Southeast Asia10.1 Southeast Asia CRISPR-Based Therapeutics Market Size (2015-2026)10.2 Southeast Asia CRISPR-Based Therapeutics Market Size by Type (2015-2020)10.3 Southeast Asia CRISPR-Based Therapeutics Market Size by Application (2015-2020)10.4 Southeast Asia CRISPR-Based Therapeutics Market Size by Country (2015-2020)10.4.1 Turkey10.4.2 Saudi Arabia10.4.3 UAE10.4.4 Rest of Middle East & Africa 11 Key Players Profiles11.1 Caribou Biosciences11.1.1 Caribou Biosciences Company Details11.1.2 Caribou Biosciences Business Overview11.1.3 Caribou Biosciences CRISPR-Based Therapeutics Introduction11.1.4 Caribou Biosciences Revenue in CRISPR-Based Therapeutics Business (2015-2020))11.1.5 Caribou Biosciences Recent Development11.2 Addgene11.2.1 Addgene Company Details11.2.2 Addgene Business Overview11.2.3 Addgene CRISPR-Based Therapeutics Introduction11.2.4 Addgene Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.2.5 Addgene Recent Development11.3 CRISPR THERAPEUTICS11.3.1 CRISPR THERAPEUTICS Company Details11.3.2 CRISPR THERAPEUTICS Business Overview11.3.3 CRISPR THERAPEUTICS CRISPR-Based Therapeutics Introduction11.3.4 CRISPR THERAPEUTICS Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.3.5 CRISPR THERAPEUTICS Recent Development11.4 Merck KGaA11.4.1 Merck KGaA Company Details11.4.2 Merck KGaA Business Overview11.4.3 Merck KGaA CRISPR-Based Therapeutics Introduction11.4.4 Merck KGaA Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.4.5 Merck KGaA Recent Development11.5 Mirus Bio LLC11.5.1 Mirus Bio LLC Company Details11.5.2 Mirus Bio LLC Business Overview11.5.3 Mirus Bio LLC CRISPR-Based Therapeutics Introduction11.5.4 Mirus Bio LLC Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.5.5 Mirus Bio LLC Recent Development11.6 Editas Medicine11.6.1 Editas Medicine Company Details11.6.2 Editas Medicine Business Overview11.6.3 Editas Medicine CRISPR-Based Therapeutics Introduction11.6.4 Editas Medicine Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.6.5 Editas Medicine Recent Development11.7 Takara Bio USA11.7.1 Takara Bio USA Company Details11.7.2 Takara Bio USA Business Overview11.7.3 Takara Bio USA CRISPR-Based Therapeutics Introduction11.7.4 Takara Bio USA Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.7.5 Takara Bio USA Recent Development11.8 Thermo Fisher Scientific11.8.1 Thermo Fisher Scientific Company Details11.8.2 Thermo Fisher Scientific Business Overview11.8.3 Thermo Fisher Scientific CRISPR-Based Therapeutics Introduction11.8.4 Thermo Fisher Scientific Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.8.5 Thermo Fisher Scientific Recent Development11.9 Horizon Discovery Group11.9.1 Horizon Discovery Group Company Details11.9.2 Horizon Discovery Group Business Overview11.9.3 Horizon Discovery Group CRISPR-Based Therapeutics Introduction11.9.4 Horizon Discovery Group Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.9.5 Horizon Discovery Group Recent Development11.10 Intellia Therapeutics11.10.1 Intellia Therapeutics Company Details11.10.2 Intellia Therapeutics Business Overview11.10.3 Intellia Therapeutics CRISPR-Based Therapeutics Introduction11.10.4 Intellia Therapeutics Revenue in CRISPR-Based Therapeutics Business (2015-2020)11.10.5 Intellia Therapeutics Recent Development11.11 GE Healthcare Dharmacon10.11.1 GE Healthcare Dharmacon Company Details10.11.2 GE Healthcare Dharmacon Business Overview10.11.3 GE Healthcare Dharmacon CRISPR-Based Therapeutics Introduction10.11.4 GE Healthcare Dharmacon Revenue in CRISPR-Based Therapeutics Business (2015-2020)10.11.5 GE Healthcare Dharmacon Recent Development 12 Analysts Viewpoints/Conclusions 13 Appendix13.1 Research Methodology13.1.1 Methodology/Research Approach13.1.2 Data Source13.2 Disclaimer13.3 Author Details

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in consulting industry.

See the original post here:
Trending Now: CRISPR-Based Therapeutics Market In-Depth Analysis Of Competitive Landscape, Executive Summary, Development Factors 2026|, Caribou...

Researchers at the University of Copenhagen in a new study presented the largest and most complex CRISPR system. Scientists believe that this system can find applications in biomedicine and biotechnology. Their work is featured in the scientific journal Molecular Cell.

CRISPR technology can be used to edit genes and revolutionized the scientific world when it was first introduced. CRISPR-Cas9 is probably the best-known CRISPR system and is widely known as gene scissors.

This is just one of many CRISPR systems in existence.

Now researchers at the University of Copenhagen (UCPH) have mapped and analyzed the atomic structure of one of the most complex CRISPR systems identified to date.

Scientists have disassembled the largest and most complex CRISPR-Cas complex seen so far. They now understand how this system works at the molecular level, said co-author Guillermo Montoya, professor at the Novo Nordisk Foundations Center for Protein Research at the University of Copenhagen (NNF CPR). Scientists have studied a complex called Cmr-, which belongs to a subgroup of so-called type III-B CRISPR-Cas complexes. The new results have already been presented to the public.

In the new study, the researchers examined the role of Cmr in the immune system and the mechanisms underlying its immune response against various bacteriophages, as well as how it is regulated.

The Cmr system, mapped by scientists in the new study, may, among other things, remove single-stranded RNA and DNA, although this will be quite difficult. But in the future, the Cmr system may still be the key to understanding the immune response of bacteria, and it may find applications in the fight against antibiotic resistance.

Read this article:
Scientists have mapped and analyzed the atomic structure of CRISPR-Cas - FREE NEWS

The team at MBL, led by MBL Senior Scientist Joshua Rosenthal and Crawford, has achieved the first gene knockout in a cephalopod using the squid Doryteuthis pealeii, an exceptionally important research organism in biology for nearly a century.

The team used CRISPR-Cas9 genome editing to knock out a pigmentation gene in squid embryos, which eliminated pigmentation in the eye and in skin cells (chromatophores) with high efficiency.

This is a critical first step toward the ability to knock out and knock in genes in cephalopods to address a host of biological questions, Rosenthal says.

Cephalopods (squid, octopus and cuttlefish) have the largest brain of all invertebrates, a distributed nervous system capable of instantaneous camouflage and sophisticated behaviors, a unique body plan, and the ability to extensively recode their own genetic information within messenger RNA, along with other distinctive features. These open many avenues for study and have applications in a wide range of fields, from evolution and development, to medicine, robotics, materials science, and artificial intelligence.

The ability to knock out a gene to test its function is an important step in developing cephalopods as genetically tractable organisms for biological research, augmenting the handful of species that currently dominate genetic studies, such as fruit flies, zebrafish, and mice.

CRISPR-Cas9 worked really well in Doryteuthis; it was surprisingly efficient, Rosenthal says. Much more challenging was delivering the CRISPR-Cas system into the one-celled squid embryo, which is surrounded by an exceedingly tough outer layer, and then raising the embryo through hatching. The team developed micro-scissors to clip the eggs surface and a beveled quartz needle to deliver the CRISPR-Cas9 reagents through the clip.

Studies with Doryteuthis pealeii have led to foundational advances in neurobiology, beginning with description of the action potential (nerve impulse) in the 1950s, a discovery for which Alan Hodgkin and Andrew Huxley became Nobel Prize laureates in 1963. For decades D. pealeii has drawn neurobiologists from all over the world to the MBL, which collects the squid from local waters.

Recently, Rosenthal and colleagues discovered extensive recoding of mRNA in the nervous system of Doryteuthis and other cephalopods. This research is under development for potential biomedical applications, such as pain management therapy.

For these reasons, the MBL Cephalopod Programs next goal is to transfer the new knockout technology to a smaller cephalopod species, Euprymna berryi (the hummingbird bobtail squid), which is relatively easy to culture to make genetic strains.

The MBL Cephalopod Program is part of the MBLs New Research Organisms Initiative, which is widening the palette of genetically tractable organisms available for research and thus expanding the universe of biological questions that can be asked.

This entry was posted on July 31, 2020 at 4:14 am and is filed under All News, Community, County, Education, More News, St. Mary's News, z 600X120 Top Ad Bottom, z 600X120 Top Ad Top. You can follow any responses to this entry through the RSS 2.0 feed.

See original here:
First Gene Knockout in a Cephalopod is Achieved at Marine Biological Laboratory by Professor Karen Crawford and Team | Southern Maryland News Net -...

BOSTON, July 28, 2020 /PRNewswire/ -- Breakthrough Properties announced that leading gene editing company, CRISPR Therapeutics, has signed a 263,500-square-foot lease agreement for the development referred to as "The 105," located at 105 West First Street and scheduled for completion in early 2022. The full-building lease transaction was executed just one year after acquisition of the site in July 2019 and four months after groundbreaking.

Breakthrough Properties was launched in 2019 by Tishman Speyer, one of the world's leading real estate developers and owners, and Bellco Capital, a prominent biotechnology investment firm. Breakthrough was formed to acquire, develop and operate the finest life science properties in leading technology centers around the world, supporting scientific innovation across biotechnology, agriculture and nutrition. On The 105 project, the company has been working closely with Tishman Speyer's Boston-based team every step of the way, from site selection to future project completion.

The 105 has been designed by the Payette architecture firm to be a best-in-class laboratory building to accommodate tenants at the forefront of life-changing science. Conveniently located near the Red Line's Broadway Station, it will feature a tailored array of amenities, including a fitness facility and outdoor terraces accessible from two floors. LEED Gold and Fitwel certifications will be sought.

Breakthrough Properties Chief Executive Officer Dan Belldegrun commented, "Our mission at Breakthrough is to deliver cutting edge facilities and environments that support companies at the forefront of life-changing science.We are thrilled to partner with CRISPR, one of the world's emerging leaders in the biotech industry, as it continues to develop therapies that change the way we fight disease. There has never been a more important time to focus on the scientific innovation and we're honored to play a small but supportive role in CRISPR's exciting future."

Tishman Speyer President & Chief Executive Officer Rob Speyer said, "With Breakthrough Properties, we are combining Tishman Speyer's global property development capabilities with Bellco Capital's recognized life sciences expertise and strong relationships. It's already proving to be a great collaboration. We believe Breakthrough will become a major global player in creating the next generation of research facilities, where important scientific advances will take place to benefit people around the world."

Since its founding in 2013, CRISPRhas quickly grown to be a leading gene-editing company focused on developing transformative gene-based medicines for serious diseases. CRISPR has established a portfolio of therapeutic programs across a broad range of disease areas, including hemoglobinopathies, oncology, regenerative medicine and rare diseases. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom.

Brokerage firm Cushman & Wakefield represented CRISPR, while Breakthrough was represented by Newmark Knight Frank.

About Breakthrough Properties (btprop.com)

Breakthrough Properties is a life science real estate development company that leverages cross-sector collaboration to deliver environments that foster innovation and scientific breakthroughs. Breakthrough combines Tishman Speyer's decades of global real estate development experience with Bellco Capital's industry-making biotechnology entrepreneurship to reimagine environments where companies can create life-changing therapies for patients. At Breakthrough, we seek to be a home for scientific discovery and innovation because we understand what you do, how you do it and why you do it.

Environments that foster innovation. Discoveries that transform lives.

For more information, please visit http://www.btprop.com.

SOURCE Breakthrough Properties

http://www.btprop.com

Go here to see the original:
Breakthrough Properties Executes Full-Building Lease With Leading Gene Editing Company for Next Generation Life Science Development in Boston's...

Dublin, July 31, 2020 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/86txdi

About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

More:
Global Market Trends in the Cell and Gene Therapy Tools and Reagents Market 2020-2024 - GlobeNewswire

The Hackett Group at EMBL Rome explores epigenetics, genome regulation and cell identity. Recently, the scientists developed a novel CRISPR molecular tool for editing the epigenome, enabling transient modifications that can switch certain genes "on" and "off" temporarily.The SARS-CoV-2 virus that has caused the COVID-19 global pandemic makes its way into a host cell via a protein known as ACE2, which is involved in a range of physiological functions in the body.

What happens when you transiently turn "off" the gene that encodes this protein? Can SARS-Cov-2 still enter the cell and cause infection? This is what Hackett and colleagues are currently exploring in animal models, to determine whether epigenetic silencing could be a treatment approach for COVID-19 in humans.Technology Networks spoke with Dr James (Jamie) Hackett, group leader at EMBL, to learn more about the CRISPR tool, how it can be used to silence ACE2 in the context of SARS-CoV-2 infection and whether there could be any adverse implications from doing so.Molly Campbell (MC): For our readers that may be unfamiliar, can you please describe what epigenetic modifications are?Jamie Hackett (JH): Epigenetic modifications are small chemical tags that are physically grafted onto DNA (or the histones that DNA wraps around) to help control how and when the DNA is used. These epigenetic modifications act as signposts that encourage a specific part of DNA, such as a gene, to be switched on or off. In other words, they help control which genes are "expressed", and which are ignored in each cell. This is important to ensure that genes that are required specifically in liver, for example, are only switched on in the liver, and not say, in the brain.MC: You are developing a CRISPR-based molecular tool to conduct epigenetic editing. Can you please tell us about this approach? How have you developed the tool and how does it work?JH: CRISPR systems normally locate a specific section of DNA in the genome and alter its genetic sequence, known as genetic "editing". Epigenetic editing uses the same principle but instead alters the epigenetic modifications at a specific region rather than the genetic sequence. This turns genes on or off in a "programmable" manner. Importantly, unlike genetic editing, epigenetic editing is largely reversible, enabling transient changes in how genes operate without changing the DNA sequence itself.MC: You plan to test the tool in mice to target airway cells that express the ACE2 protein. Can you talk to us about the rationale behind this?JH: ACE2 is a protein that sits on the outside of many cells and is normally involved in controlling blood pressure. However, the COVID-19 virus hijacks ACE2 by using it as a docking site that enables entry of the virus into a cell. If the gene ACE2 is switched OFF, this should remove the access point for COVID-19 and restrict infection. To test this possibility, we will use mouse models where we attempt to epigenetically switch off ACE2, which will help inform us whether this could be a viable strategy in humans in the future.

MC: Could there be adverse effects from targeting the ACE2 protein, as it is involved in several physiological processes in humans, for example? How will you explore and monitor this?JH: Impaired levels of ACE2 over long periods are linked with elevated blood pressure. However, over short-term periods loss of ACE2 appears to be relatively tolerable. This is one reason why a reversible "epigenetic" approach could be appealing since it would only temporality deplete ACE2 from cells, potentially to provide protection during high risk periods, before allowing it to return to its original status at the appropriate time.MC: What broader applications might this tool have, beyond SARS-CoV-2?JH: The same technology can, in principle, be applied to change the expression of genes other than ACE2, that are linked with disease. We are at the very beginning of exploring the potential of this, so it is not clear what realistic expectations are, but there is nonetheless great excitement about such precision strategies. For example, diseases where one of the two gene copies is a "mutant", such as Huntingtons disease, could be targets. Here it is hoped to be possible to epigenetically switch off only the mutant version of the gene, leaving the normal copy on. This scenario is predicted to help mitigate symptoms in a very precise and specific way. Conversely, in the neurological disorder Fragile X syndrome, the FMR1 gene has become inappropriately silenced (switched off). Epigenetic editing can be applied to selectively reactivate this gene to switch it on, with initial indications being that this helps restore neuronal functions. Jamie Hackett was speaking to Molly Campbell, Science Writer for Technology Networks.

Go here to see the original:
Silencing the SARS-CoV-2 Receptor With CRISPR and Epigenetic Modifications - Technology Networks

There are good investments and there are great investments. CRISPR Therapeutics (NASDAQ:CRSP) stock certainly qualifies as the latter.

This is a company that, four years after it went public, has only been profitable for one year, yet its future is so promising that its stock is trading for 540% more than it did in 2016.

What's the big deal about CRISPR Therapeutics? The biopharmaceutical company says it is using breakthrough gene-altering therapies to treat diseases such as sickle cell disease (SCD) and beta-thalassemia, both of which are inherited blood disorders that don't have a cure and require frequent blood transfusions. The company is also working on gene therapies to treat type 1 diabetes, muscular dystrophy, cystic fibrosis, multiple myeloma, and solid tumors in pancreatic cancer and lung cancer.

Image source: Getty Images.

CRISPR Therapeutics is actually named for the technology it uses: CRISPR stands for "clusters of regularly interspaced short palindromic repeats." The gene-editing technology uses Cas9 proteins to locate a sequenceof DNA within a cell and alter it.

Though CRISPR Therapeutics has yet to bring a product to market, some of its clinical trials have had amazing results. In June, the Swiss company announced that in a joint trial with Vertex Pharmaceuticals (NASDAQ:VRTX), five patients with beta-thalassemia and two patients with sickle cell disease were treated with gene therapy CTX001.

Two of the early beta-thalassemia patients are now transfusion independent 15 months afterward. The first SCD patient in the trial is transfusion independent and free of vaso-occlusive crises (VOCs), a painful condition when blood vessels are blocked by sickled red blood cells, seven months after his dose of CTX001.

Beta-thalassemia, which reduces the body's production of hemoglobin, is extremely rare. Sickle cell anemia is common among African Americans but also can affect Latinos and people of Indian, Asian, Mediterranean backgrounds. The U.S. Department of Health and Human Services says 300,000 babies worldwide are born every year with the disease and 100,000 people in the United States are currently living with the disease.

While the results are quite promising, the study is still in its infancy. .

If you had invested $100 in CRISPR Therapeutics stock when it went public in 2016, how much would that be worth today?

By the end of the day on Oct. 19, 2016, the day CRISPR Therapeutics went public, the stock was trading at $14.09, you would have bought seven shares. Assuming you bought at that price, your original $98.63 investment would be worth $632.45 as of the close of trading Friday when the stock went for $90.35 per share. That's a gain of 541%.

CRISPR Therapeutics isn't the only biotech to use CRISPR-Cas9 technology. Others include Editas Medicine (NASDAQ:EDIT) and Intellia Therapeutics (NASDAQ:NTLA), both of which went public in 2016. Neither of those has done quite as well as CRISPR Therapeutics since its IPO.

Compared to a biotech ETF such as the iShares NASDAQ Biotechnology ETF (NASDAQ:IBB), CRISPR has shined. The ETF closed at $89.16 on the day of CRISPR's IPO. As of Friday's close, IBB was at $136.41. If you had invested $100 on Oct. 19, 2016, you would have a return of only 36%.

CRSP data by YCharts

Clinical-stage biotech stocks are inherently risky plays because there are so many hurdles these companies have to clear before they can make money. The therapies have to be approved by the Food and Drug Administration (FDA) and many therapies look promising only to fail in late-stage clinical trials.

CRISPR Therapeutics looks like a solid bet, though, both from a cash standpoint and in its strength of pipeline. The company has four candidates already in trials.It is already making money, though not a lot of it. Last year, CRISPR Therapeutics generated net income of $66.8 million, thanks to $289.5 million in collaboration revenue.

The other major question for clinical-stage biotechs is whether they have enough capital to pay for research and development until the therapies pay off. Last quarter, the company burned through $54 million in cash. However, CRISPR Therapeutics says it has more than $900 million left, so it can continue that burn rate for more than four years. The possibility that CRISPR Therapeutics' technology could actually cure diseases, not just treat them, easily makes this a risk worth taking.

Original post:
If You Invested $100 in CRISPR Therapeutics' IPO, This Is How Much Money You'd Have Now - The Motley Fool

New Jersey, United States,- The research report on Crispr And Crispr Associated Genes market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The unit cost deployed by these producers in various regions during the estimated timeframe is also mentioned in the report.

Significant information pertaining to the product volume and consumption value is enlisted in the document. Additionally, the report contains details regarding the consumption graphs, Individual sale prices, and import & export activities. Additional information concerning the production and consumption patterns are presented in the report.

In market segmentation by manufacturers, the report covers the following companies-

Exploring the growth rate over a period

Business owners looking to scale up their business can refer this report that contains data regarding the rise in sales within a given consumer base for the forecast period, 2020 to 2027. Product owners can use this information along with the driving factors such as demographics and revenue generated from other products discussed in the report to get a better analysis of their products and services. Besides, the research analysts have compared the market growth rate with product sales to enable business owners to determine the success or failure of a specific product or service.

By Type

By Application

Regions Covered in the Global Crispr And Crispr Associated Genes Market:

The Middle East and Africa (GCC Countries and Egypt)

North America (the United States, Mexico, and Canada)

South America (Brazil etc.)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Highlights of the Report:

Accurate market size and CAGR forecasts for the period 2020-2026

Identification and in-depth assessment of growth opportunities in key segments and regions

Detailed company profiling of top players of the global Crispr And Crispr Associated Genes market

Exhaustive research on innovation and other trends of the global Crispr And Crispr Associated Genes market

Reliable industry value chain and supply chain analysis

Comprehensive analysis of important growth drivers, restraints, challenges, and growth prospects

The scope of the Report:

The report offers a complete company profiling of leading players competing in the global Crispr And Crispr Associated Genes marketwith a high focus on the share, gross margin, net profit, sales, product portfolio, new applications, recent developments, and several other factors. It also throws light on the vendor landscape to help players become aware of future competitive changes in the global Crispr And Crispr Associated Genes market.

Reasons to Buy the Report:

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

See the rest here:
Crispr And Crispr Associated Genes Market Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2027 - Owned

CRISPR Therapeutics AG (CRSP) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2020. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.

The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower.

While the sustainability of the immediate price change and future earnings expectations will mostly depend on management's discussion of business conditions on the earnings call, it's worth handicapping the probability of a positive EPS surprise.

Zacks Consensus Estimate

This company is expected to post quarterly loss of $0.92 per share in its upcoming report, which represents a year-over-year change of +8.9%.

Revenues are expected to be $23.08 million, up 7112.5% from the year-ago quarter.

Estimate Revisions Trend

The consensus EPS estimate for the quarter has been revised 1.24% higher over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period.

Investors should keep in mind that the direction of estimate revisions by each of the covering analysts may not always get reflected in the aggregate change.

Price, Consensus and EPS Surprise

Earnings Whisper

Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. Our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction) -- has this insight at its core.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only.

A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP.

Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell).

How Have the Numbers Shaped Up for CRISPR Therapeutics AG?

For CRISPR Therapeutics AG, the Most Accurate Estimate is higher than the Zacks Consensus Estimate, suggesting that analysts have recently become bullish on the company's earnings prospects. This has resulted in an Earnings ESP of +13.78%.

Story continues

On the other hand, the stock currently carries a Zacks Rank of #4.

So, this combination makes it difficult to conclusively predict that CRISPR Therapeutics AG will beat the consensus EPS estimate.

Does Earnings Surprise History Hold Any Clue?

Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number.

For the last reported quarter, it was expected that CRISPR Therapeutics AG would post a loss of $1.09 per share when it actually produced a loss of $1.15, delivering a surprise of -5.50%.

Over the last four quarters, the company has beaten consensus EPS estimates two times.

Bottom Line

An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss.

That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

CRISPR Therapeutics AG doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free reportCRISPR Therapeutics AG (CRSP) : Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment Research

Go here to see the original:
Will CRISPR Therapeutics AG (CRSP) Report Negative Q2 Earnings? What You Should Know - Yahoo Finance

The 105. Image courtesy of Payette

One year after forming a firm to acquire, develop and operate life sciences assets, Breakthrough Properties has signed a 263,500-square-foot lease agreement for its first ground-up development, The 105 in Bostons Seaport District. Located at 105 W. First St., the building will be fully leased by gene editing company CRISPR Therapeutics once it is completed in 2022.

READ ALSO: Life Sciences Real Estate Thrives Amid Pandemic

Breakthrough Properties was launched in 2019 by real estate development firm Tishman Speyer and Bellco Capital, a biotech investment company. The firm is targeting life science developments in leading tech markets around the globe for companies involved in the biotech, agriculture and nutrition sectors. Breakthrough acquired the Seaport property in July 2019 and broke ground on The 105 in March 2020. The firm has been working closely with Tishman Speyers Boston-based team throughout the process, including site selection, and will continue the close working relationship through the projects completion.

CRISPR, which currently has its R&D operations in Cambridge, Mass., plans to consolidate various office and laboratory operations in the Greater Boston area into the new Seaport building. The company was founded in 2013 and has grown into a leading gene-editing company focused on developing transformative gene-based medicines for a broad range of diseases. The parent company, CRISPR Therapeutics AG, is headquartered in Zurich and the wholly owned U.S. subsidiary CRISPR Therapeutics also has business offices in San Francisco and London. Officials said this week that the single Boston location should support its anticipated growth for five to seven years from occupancy in 2022. CRISPR also announced Monday in its second-quarter 2020 earnings report that it is building a new cell therapy and manufacturing facility in Framingham, Mass.

Breakthrough Properties CEO Dan Belldegrun said Breakthroughs mission is to deliver cutting-edge facilities and environments that support companies like CRISPR. He noted in prepared remarks that the company was honored to play a small but supportive role in CRISPRs future as it develops therapies that change the way we fight disease.

Located on the A Street Corridor, The 105 is located near the Red Lines Broadway Station and a 10-minute ride from Kendall Square in Cambridge. Designed by the Payette architecture firm to be a best-in-class laboratory asset, Breakthrough will be seeking LEED Gold and Fitwell certifications for the building. Amenities will include a fitness center, indoor bicycle room, outdoor terraces accessible from the second and third floors, meeting space, and a locker room with showers.

Cushman & Wakefield represented CRISPR and Breakthrough was represented by Newmark Knight Frank in the lease transaction.

Last month, Hines also entered the life sciences market, unveiling a new partnership with 2ML Real Estate to develop a biotech and mixed-use hub in Houston. Levit Green will span more than 52 acres and be adjacent to the Texas Medical Center, the worlds largest cluster of medical facilities and businesses. 2ML is supplying the land for the project. Preliminary plans call for a mix of research, office, residential, retail and dining uses, along with outdoor amenities and green space.

Hines and Tishman Speyer are among a growing group of commercial real estate developers expanding recently into the burgeoning life sciences sector. Boston Properties teamed up with Alexandria Real Estate Equities in January to develop a 1.7 million-square-foot life science campus in South San Francisco. In October, LaSalle Investment Management took a stake in the San Diego headquarters of Illumina, a DNA sequencing and array-based technologies firm. Last summer, Thor Equities launched its Thor Sciences division to invest in biotech properties.

See the article here:
Breakthrough Properties Completes Full-Building Lease in Boston - Commercial Property Executive

Scientists at the University of WisconsinMadison have published a proof-of-concept method to correct an inherited form of macular degeneration that causes blindness, and that is currently untreatable.

Andrew Hellpap608-225-5024ahellpap@uwhealth.org

The researchers were able to correct the disease in stem cells from patients with BEST1 mutations by overwhelming broken copies of the gene with many functional copies of BEST1. This approach worked for most, but not all, of the BEST1 mutations that they tested. As an alternative approach for mutations that did not respond to this gene augmentation method, the team used CRISPR-Cas9 gene editing to target and correct the mutations.

A paper chronicling the research, co-led by David Gamm, MD, PhD, professor of ophthalmology and visual sciences in the School of Medicine and Public Health, was published online July 23 in the American Journal of Human Genetics. The study was also led by Kris Saha, PhD, associate professor of biomedical engineering and Wisconsin Institute for Discovery, and Bikash Pattnaik, PhD, assistant professor of pediatrics.

This BEST1 gene encodes a protein that regulates the movement of chloride across a layer of the retina called the retinal pigment epithelium (RPE). Best disease is dominant, meaning that people who inherit only one faulty copy of the BEST1 gene from either their mother or their father will develop the disorder. Mutations in BEST1 cause the retinal layer to break down, resulting in blurred central vision that progresses to irreversible vision loss.

People with Best disease have a wide range of mutations that can affect different parts of the protein, all of which were thought to require complex, individualized gene therapies to fix them, Gamm said. We found that many of these mutations were actually very sensitive to a broader gene therapy method that is already established for other retinal diseases.

Fixing a dominant genetic disease via gene therapy typically requires precise removal or repair of the nonfunctional gene without causing harm to the functional gene a difficult task that is frequently unsuccessful. In contrast, recessive genetic diseases that arise when a person inherits two nonfunctional genes one from each parent can be corrected by a technique called gene augmentation. This well-established process introduces a functional copy of the gene to fill the void.

To use another analogy, dominant mutations produce workers that actively look to sabotage the efforts of their capable coworkers, whereas recessive mutations produce proteins that never show up for work at all, Gamm said. As it turns out, the latter situation is usually simpler to treat than the former.

A team of researchers at the McPherson Eye Research Institute, which Gamm directs, hypothesized that it may be possible to adequately dilute the influence of the nonfunctional BEST1 protein by counter-balancing it with many functional copies of BEST1 protein through gene augmentation.

In the lab, the approach worked in RPE cells derived from induced pluripotent stem cells of patients with most, but not all, of the BEST1 gene mutations they tested. Where gene augmentation did not succeed, the team was able to correct the dysfunction using CRISPR-Cas9 gene editing.

The research was carried out in large part by Divya Sinha, PhD, an assistant scientist in Gamms lab, Ben Steyer, a former MD-PhD student in Sahas lab, and Pawan Shahi, PhD, postdoctoral research associate in Pattnaiks lab. The research team also included Sushmita Roy, PhD, associate professor of biostatics and medical informatics at the UW School of Medicine and Public Health and Wisconsin Institute for Discovery.

The scientists demonstrated that their two-pronged gene therapy strategy may hold potential to treat all Best disease mutations in a highly effective manner.

We were able to reverse the disease in all the cell lines using one method or the other, Gamm said. We were also able to determine which mutations were likely to respond to the first-line gene augmentation strategy, and which would be better served with the second-line gene editing approach.

An additional benefit came into focus as this research progressed, according to Gamm.

Our findings also could be applicable to some dominant genetic mutations that affect tissues elsewhere in the body, he said. Its very exciting.

More here:
UW researchers devise approach to treat rare, incurable form of blindness - University of Wisconsin-Madison

DUBLIN--(BUSINESS WIRE)--The "Cell and Gene Therapy Tools, and Reagents: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Gene and cell therapy are emerging as important tools to treat human health. Techniques such as CAR-T therapy have emerged as key ways of treating many different types of cancers. The promise of gene therapy using technologies such as CRISPR is starting to be realized in clinical trials, and markets are scaling up to treat other diseases as well, particularly rare gene-based diseases. As these therapies are coming to the fore, a new market for tools to develop these therapies using standard methodologies is emerging. This report will cover what those tools are, how they impact the larger life science tools market, and how they will evolve over the next five years.

The scope of this study encompasses an investigation of the market's cell and gene therapy tools such as GMP proteins, media, cell separation and activation reagents, viral and non-viral, cytokine release syndrome monitoring products, GMP antibodies, leukapheresis instrumentation, immunoassays (multiplex and singleplex) and bioreactors. This research analyzes each tool type, determines its current market status, examines its impact on future markets, and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed. The report analyzes the industry on a worldwide basis, from both application and demand perspectives, in the major regions of the world.

The Report Includes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Breakdown by Region

Chapter 5 Market Breakdown by End User

Chapter 6 Government Regulations

Chapter 7 Patent Review/New Developments

Chapter 8 Analysis of Market Opportunities

Chapter 9 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/nk3d0z

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

See more here:
Global Cell and Gene Therapy Tools and Reagents Market 2020: Analysis of Market Opportunities - ResearchAndMarkets.com - Business Wire